Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade) [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
Rinvoq sales were about $1.1 billion in the first quarter of 2024, up 59.3% from the previous year. The company's management raised its 2024 adjusted earnings guidance from $10.97 - $11.17 to $11.13 - $11.33. AbbVie has a rich portfolio of experimental drugs, one of the most promising of which is Epkinly, which was developed in partnership with Genmab. As a result, I am upgrading AbbVie stock's rating from 'Hold' to 'Buy'. AbbVie ( NYSE: ABBV ) is one of the largest pharmaceutical companies in the world, holding one of the leading positions in the global autoimmune and neurological disorders therapeutics markets. Investment thesis Since the publication of my last article in Recommended For You Recommended For You About ABBV Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress [Yahoo! Finance]Yahoo! Finance
- Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressBusiness Wire
- Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Quarter of 2024 [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Quarter of 2024GlobeNewswire